Annual General Meeting Presentation 2017
Annual General Meeting - 30 November 2017
Annual General Meeting - 30 November 2017 will be held on Friday 30 November 2017 at 5pm at Gadens Lawyers, Level 25, 600 Bourke Street, Melbourne. A letter and the notice of AGM were mailed to all shareholders on Friday 3rd November 2017.
More information can be found on the following:
A New Appointment to the Board of Directors - 19 June 2017
Edited version of the presentation given at the AGM 25 November 2016
Annual General Meeting - 25 November 2016
Sementis' Annual General Meeting (AGM) will be held on Friday 25 November 2016 at 10am at Gadens Lawyers, Level 25, 600 Bourke Street, Melbourne. A letter and the notice of AGM were mailed to all shareholders on Monday 31st October 2016.
More information can be found on the following:
Edited version of the presentation given at the AGM 30 November 2015
Annual General Meeting - 30 November 2015
Sementis' Annual General Meeting (AGM) will be held on Monday 30 November 2015 at 10am at Gadens Lawyers, Level 25, 600 Bourke Street, Melbourne. A letter and the notice of AGM were mailed to all shareholders on Friday 30 October 2015.
More information can be found on the following:
R&D ATO REFUND
13 October 2015
More information can be found on the following Link
R&D ATO REFUND
07 September 2014
More information can be found on the following Link
MANAGEMENT TEAM CHANGE FOR THE NEXT PHASE OF SEMENTIS’ DEVELOPMENT
24 June 2014
More information can be found on the following Link
INITIAL SUCCESS IN CHIKUNGUNYA PROOF OF CONCEPT STUDIES 10 NOV 2013
10 November 2013
Sementis is pleased to announce that its Chikungunya vaccine has succeeded in Proof of Concept and is progressing into further challenge models.
A PEANUT ALLERGY VACCINE ANIMATION IS NOW AVAILABLE ON OUR WEBSITE
24 December 2012
An animation on how Sementis' Peanut Allergy Vaccine works is now available on this website. The purpose of the animation is to help the non-scientist understand the mechanism behind the product. We welcome your feedback which can be sent on the CONTACT US link in the main menu bar. The animation can be found on the folloing Link
A review of the 'Peanut Allergy Field' prepared by Sementis' Dr Paul Howley, Assoc Prof John Hayball and Dr Darren Miller has been been accepted for publication in the peered reviewed journal Expert Reviews of Vaccines. This represents a significant validation of Dr Howley's strategy towards Peanut Allergy and Sementis' approach to combating the condition.
Sementis is very proud to announce the achievement of over $2,500,000 in its first fund rasising round and the closing of this round. The funds raised in this round are being committed to Proof of Concept Studies on our vaccine pipeline. Following this work Sementis will undertake pre-clinical studies and human clinical trials.
Sementis is proud to announce the appointment of Maurice O'Shannassy to the Board as a non-executive director. He brings a wealth of experience from the financial services industry and a range of other board level roles. Further details on Maurice and the rest of the board can be found on the link below...
Sementis is proud to announce the achievement of over $1,000,000 in its first fund rasising round. Sementis seeks to raise a minimum of $2,500,000 in this round in order to complete Proof of Concept Studies on its vaccines. This round will open the door to pre-clinical studies and human clinical trials.
Sementis has successfully filed a provisional patent on its Peanut Allergy Vaccine REF PATENT. Further details on the Peanut Allergy Vaccine can be found on the following link...
Sementis is pleased to announce the appointment of Dr Tom Quirk to the Board as a non-executive director. He brings a weath of experience in start-up biotech and solid networks in academia and industry. Tom is the first non-executive director to join the Sementis Board. Further details on Tom and the rest of the board can be found on the following link...